Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Finished Goods: 2019-2025

Historic Finished Goods for Aytu Biopharma (AYTU) over the last 7 years, with Sep 2025 value amounting to $7.9 million.

  • Aytu Biopharma's Finished Goods rose 2.74% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year increase of 2.74%. This contributed to the annual value of $8.9 million for FY2025, which is 45.33% up from last year.
  • Latest data reveals that Aytu Biopharma reported Finished Goods of $7.9 million as of Q3 2025, which was down 11.99% from $8.9 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Finished Goods peaked at $12.0 million during Q4 2021, and registered a low of $6.2 million during Q2 2024.
  • For the 3-year period, Aytu Biopharma's Finished Goods averaged around $7.8 million, with its median value being $7.7 million (2023).
  • Per our database at Business Quant, Aytu Biopharma's Finished Goods spiked by 209.71% in 2021 and then crashed by 32.89% in 2022.
  • Over the past 5 years, Aytu Biopharma's Finished Goods (Quarterly) stood at $12.0 million in 2021, then crashed by 30.08% to $8.4 million in 2022, then rose by 3.73% to $8.7 million in 2023, then fell by 13.66% to $7.5 million in 2024, then grew by 2.74% to $7.9 million in 2025.
  • Its Finished Goods was $7.9 million in Q3 2025, compared to $8.9 million in Q2 2025 and $8.5 million in Q1 2025.